FRI0196 EFFICACY OF RITUXIMAB RETREATMENT IN CLINICAL PRACTICE: DATA FROM THE CERERRA COLLABORATION
K. Chatzidionysiou 1,*R. F. van Vollenhoven 1E. Nasonov 2G. Lukina 2M. L. Hetland 3U. Tarp 3C. Gabay 4P. L. C. M. van Riel 5D. C. Nordström 6J. Gomez-Reino 7K. Pavelka 8M. Tomsic 9E. Lie 10T. K. Kvien 10
1Karolinska Institute, Stockholm, Sweden, 2Inst of Rheumatology, Moscow, Russian Federation, 3DANBIO, Hvidovre/Glostrup Univ Hosp, Copenhagen, Denmark, 4Univ Hosp , Geneva, Switzerland, 5Radboud Univ, Nijmegen, Netherlands, 6ROB-FIN Univ Hosp, Helsinki, Finland, 7Univ De Santiago, Coruna, Spain, 8Charles Univ, Prague, Czech Republic, 9Univ Med Center, Ljubljana, Slovenia, 10Diakonhjemmet, Oslo, Norway
Background: Rituximab (RTX) is used in the treatment of RA, most often after failure of one or more TNF inhibitors. The optimal regimen for retreatment of RTX has not yet been established.
Objectives: To analyze the efficacy of retreatment with RTX within 12 months after the first treatment and to identify predictors of response.
Methods: Ten European registries submitted anonymized datasets with baseline, 3, 6, 9 and 12 month data for patients who had started RTX. These datasets were pooled and analyzed. Heterogeneity between countries was analyzed by ANOVA. Predictors of response were identified by logistic regression analyses.
Results: Baseline data were available for 2048 patients with RA who had been treated with RTX. The mean (SD) age / disease duration of patients was 53.8 (13.3) / 12.1 (8.9) years. 80.4% of them were female, 85.6% RF positive and 76.6% (448 out of 585 patients) were anti-CCP positive. The numbers of confirmed double seropositive and seronegative patients were 367 and 59 respectively. The mean (SD) numbers of previous DMARDs and biologics were 2.7 (1.6) and 1.1 (1.1) respectively. Significant heterogeneity was noted between countries for all baseline characteristics. Significant reduction of DAS28 was observed at 6 months [ΔDAS28 =1.95 (SD=1.5)]. At 6 months RF-positive patients achieved significantly better results compared to RF-negative ones, as did ACPA-positive patients compared to ACPA-negative ones and double-positive compared to double-negative ones (Table 1).
Data were available for 350 patients who were retreated with RTX during the first 12 months. At 12 months the retreated patients had a significantly greater mean reduction in DAS28 compared to the same patients at 6 months [ΔDAS28 2.2 (SD=1.4) vs 1.9 (SD=1.4) p<0.005]. Double positive patients who had received retreatment achieved significantly greater reductions in DAS28 at 12 months compared to double seronegative retreated patients (Table 1).
Predictors of EULAR Good Response at 6 months were found to be positive ACPA (p=0.02), lower number of previous DMARDs (p=0.0003) and biologics (p=0.001), and at 12 months lower number of prior biologics (p=0.02) and lower HAQ at baseline (p=0.01).
|
DAS28 improvement at 6 months(n=810) |
DAS28 improvement at 12 months (retreated patients only) (n=124) | ||||||
|
|
Positive |
Negative |
p |
Positive |
Negative |
p | ||
|
RF |
2.0±1.5 |
1.7±1.5 |
0.02 |
2.3±1.4 |
1.8±1.2 |
NS | ||
|
ACPA |
2.1±1.4 |
1.5±1.5 |
0.006 |
2.6±1.3 |
2.1±1.3 |
NS | ||
|
DOUBLE |
2.1±1.4 |
1.4±1.5 |
0.009 |
2.8±1.2 |
1.3±0.7 |
0.004 | ||
Table 1. Mean ± SD reductions in DAS28 at 6 and 12 months by serology.
Conclusion: Patients who were retreated with RTX during the first 12 months achieved significantly better DAS28 improvements at 12 months than at 6 months. Seropositivity was associated with greater DAS28 improvements at 6 and 12 months. Lower number of prior biologics and lower HAQ at baseline predicted 12-month EULAR Good Response.
Disclosure of Interest: None declared